French biotech company Ciloa wins the 2020 “Sanofi iTech Awards”.
The winning project is based on the unique innovation developed by Ciloa, which uses its customized exosomes for therapeutic purposes.
The “Sanofi iTech Awards” program funds and supports projects related to the development of innovative technologies in Healthcare that may lead to a subsequent research collaboration between Sanofi and Ciloa.
SAN DIEGO, Feb. 9, 2021 — Nucleus Biologics™, The Cell Performance Company™, today announced the availability of NB-AIR™, the world’s first Artificial Intelligence Research platform for optimizing cell culture formulations for cell and gene therapies. Leveraging cutting-edge AI algorithms, the system empowers scientists to create optimized formulas based on meta-analysis of peer-reviewed articles. AI guided formulations will allow scientists to improve the performance of their cell therapy and shorten the time to get these lifesaving therapies into patients faster. [Read more…]
On February 5, 2021, the U.S. FDA granted approval of Breyanzi (lisocabtagene maraleucel) to Juno Therapeutics, a Bristol-Myers Squibb Company. Breyanzi is a chimeric antigen receptor (CAR) T cell therapy approved for the treatment of adults with relapsed or refractory large-B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. [Read more…]
Dr. Giacomo Lanzoni to speak on a live webcast hosted tonight, Wednesday, February 3, 2021, courtesy of The American Academy of Stem Cell Physicians!
The American Academy of Stem Cell Physicians (AASCP) offers various events tailored for doctors and the research community. It is constantly keeping up with the latest developments in regenerative medicine, including diagnosis, treatments, and prevention of diseases. In an exciting webcast to be held tonight, Wednesday, February 3, 2021, the AASCP will feature renowned researcher, Dr. Giacomo Lanzoni. [Read more…]